In addition, U.S. Food and Drug Administration (FDA) approved the combination therapy, Orkambi (lumacaftor/ivacaftor), to treat the underlying cause of CF in people aged 12 or older who are homozygous for F508del-CFTR mutation on July 2, 2015 (www.vrtx.com). Here, CFTR is linked to cystic fibrosis.